Protara Therapeutics, Inc.
TARA
$3.11
$0.010.32%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 19.87M | 18.32M | 17.45M | 17.30M | 17.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.35M | 51.43M | 49.15M | 45.88M | 44.25M |
| Operating Income | -57.35M | -51.43M | -49.15M | -45.88M | -44.25M |
| Income Before Tax | -50.86M | -45.42M | -44.60M | -42.05M | -40.69M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -50.86 | -45.42 | -44.60 | -42.05 | -40.69 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -50.86M | -45.42M | -44.60M | -42.05M | -40.69M |
| EBIT | -57.35M | -51.43M | -49.15M | -45.88M | -44.25M |
| EBITDA | -57.01M | -51.10M | -48.82M | -45.53M | -43.90M |
| EPS Basic | -1.63 | -1.73 | -2.41 | -2.82 | -3.19 |
| Normalized Basic EPS | -1.02 | -1.08 | -1.50 | -1.76 | -1.99 |
| EPS Diluted | -1.63 | -1.73 | -2.41 | -2.82 | -3.19 |
| Normalized Diluted EPS | -1.02 | -1.08 | -1.50 | -1.76 | -1.99 |
| Average Basic Shares Outstanding | 131.74M | 110.70M | 81.42M | 66.35M | 55.37M |
| Average Diluted Shares Outstanding | 131.74M | 110.70M | 81.42M | 66.35M | 55.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |